Hypoparathyroidism Treatment Market – By Product Type (Supplements [Calcium, Vitamin D, Magnesium, Zinc], Parathyroid Hormone), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) & Forecast, 2024 – 2032

Hypoparathyroidism Treatment Market Size

Hypoparathyroidism Treatment Market was valued at USD 1.3 billion in 2023 and is estimated to register a CAGR of 6.9% from 2024 to 2032. The market has witnessed significant growth over the recent years, driven by the increasing cases of hypoparathyroid disorders, rising number of thoracic surgeries and thyroid gland disorders, and increasing cases of thyroid cancer worldwide. Additionally, advancements in diagnostic technologies are enabling more accurate and timely diagnosis of hypoparathyroidism, leading to a higher number of patients seeking treatment. Further, growing awareness among healthcare professionals and patients about the importance of early detection and treatment is driving market growth by encouraging more proactive management of hypoparathyroidism.

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production or secretion of parathyroid hormone (PTH) by the parathyroid glands. These small glands are located in the neck, behind the thyroid gland, and play a crucial role in regulating calcium and phosphorus levels in the body. This imbalance disrupts various physiological processes in the body, affecting the muscles, nerves, and bones.

Hypoparathyroidism Treatment Market Trends

• Increasing incidence of hypoparathyroidism is a significant driving factor. The prevalence of hypoparathyroidism is an estimated 37 per 100 000 person-years in the U.S. Additionally, it is estimated that approximately 7.6% of all thyroid related surgeries result in hypoparathyroidism.
   
• Thus, as the number of cases increases, the demand for treatment also rises, thereby driving the market growth.
   
• Further, growing awareness about parathyroid disorders, their symptoms, and potential complications has led to an increased number of patients seeking medical advice and treatment. This awareness results in a higher number of diagnosed cases and, consequently, a greater demand for hypoparathyroidism treatments.
   

However, the high cost of treatment can impose a significant financial burden on patients and their families. Consequently, due to financial constraints, some individuals delay seeking medical attention or avoid necessary tests and treatments for hypoparathyroidism, thereby impeding market growth to some extent.
 

Hypoparathyroidism Treatment Market Analysis

Based on the product type, the global hypoparathyroidism treatment industry is segmented into supplements and parathyroid hormone. The supplements segment is further divided into calcium supplements, vitamin D supplements, and other supplements. The supplements segment garnered USD 888.2 million revenue in the year 2023.
 

• The dominance of the segment can be attributed to the well-established safety profile of supplements, ease of availability, and use in conjunction to optimize the overall treatment.
   
• Further, these supplements are widely prescribed by healthcare providers and recommended in clinical guidelines for managing the condition.
   
• Thus, wide adoption of supplements as a standard treatment in hypoparathyroidism drives the segmental growth.
   

Based on the route of administration, the global hypoparathyroidism treatment market is classified into oral and parenteral. The oral route segment dominated the market and accounted for 66.5% market share in the year 2023.
 

• Oral administration is non-invasive, which means it doesn't involve injections or surgical procedures. For individuals with hypoparathyroidism who require long-term treatment, oral route provide a less discomforting and more acceptable option.
   
• Additionally, oral medications can be easily formulated to provide accurate and consistent dosages, allowing healthcare providers to prescribe precise amounts tailored to each patient's needs. This accuracy is crucial in managing mineral imbalances in hypoparathyroidism.
   

Based on distribution channel, the global market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market and is expected to reach USD 1 billion by 2032.
 

• High segment growth is primarily fueled by the well-equipped nature of the hospital pharmacies to handle the compounding and dispensing of these specialized medications, ensuring that patients receive the exact formulations prescribed by their healthcare providers.
   
• Moreover, hospital pharmacies are staffed by pharmacists with clinical expertise who work closely with healthcare providers to ensure accurate and safe medication management for patients with complex condition of hypoparathyroidism.
   
• Further, high volume of patients visiting hospitals, drives the segmental growth of hospital pharmacy segment.
   

North America hypoparathyroidism treatment market is expected to grow at 6.8% CAGR during the analysis period.
 

• Presence of advanced healthcare infrastructure with access to state-of-the-art medical facilities, specialized healthcare professionals, and research institutions in the region facilitates early diagnosis and effective treatment of hypoparathyroidism.
   
• Furthermore, the region is a hub for pharmaceutical research and development. Several pharmaceutical companies and research institutions are dedicated to developing treatments for rare diseases, including hypoparathyroidism.
   
• All these factors together contribute to the dominance of North America in the global hypoparathyroidism market.
   

Hypoparathyroidism Treatment Market Share

The hypoparathyroidism treatment industry is characterized by a dynamic interplay among pharmaceutical companies striving to capture a significant share. Companies such as Takeda Pharmaceutical Company Ltd., Ascendis Pharma, and F. Hoffman-La Roche Ltd. are notable players, with well-established product portfolios. These players are constantly involved in strategic alliances, collaborations, and market expansion initiatives to strengthen their foothold in the market.
 

Hypoparathyroidism Treatment Market Companies

Market players operating in the hypoparathyroidism treatment are as mentioned below:

• Ascendis Pharma A/S
• Amgen Inc.
• BioNTech SE
• Bristol-Myers Squibb Company
• Entera Bio Ltd.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• SK biopharmaceuticals Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited.
   

Hypoparathyroidism Treatment Industry News:

• In November 2018, Ascendis Pharma formed VISEN Pharmaceuticals to collaborate on the development, production, and commercialization of the company's TransCon Endocrinology Rare illness medicine for hypoparathyroidism in Greater China. This helped the company strengthen its foothold in Asia Pacific region.
   

The global hypoparathyroidism treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Supplements
  • Calcium supplements
  • Vitamin D supplements
  • Other supplements
    • Magnesium
    • Zinc 
• Parathyroid hormone

Market, By Route of Administration

• Oral
• Parenteral

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa